RegenXBio Inc. ((RGNX)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
RegenXBio Inc. is conducting a study titled ‘Anti-AAV8 Antibody Assessment Study of Boys With Duchenne Muscular Dystrophy Aged 0 to <12 Years.' The study aims to evaluate the prevalence of anti-adeno-associated serotype 8 (AAV8) antibodies in boys with Duchenne muscular dystrophy (DMD), a significant step in understanding immune responses in this patient population.
The intervention being tested is a diagnostic test named AAV8 DetectCDx. This in vitro diagnostic assay is designed to detect antibodies to AAV8 in human serum specimens, providing crucial data for future therapeutic developments.
The study follows an observational cohort model with a prospective time perspective. This means participants are observed over time to assess the presence of AAV8 antibodies, without any intervention altering their natural course.
The study began on January 4, 2023, with its primary completion and estimated completion dates yet to be announced. The most recent update was submitted on April 2, 2025, indicating ongoing recruitment and data collection.
This study could impact RegenXBio’s stock performance positively by showcasing its commitment to advancing DMD research. It may also influence investor sentiment by highlighting potential future therapeutic avenues, especially in a competitive field where innovation is key.
The study is ongoing, with further details available on the ClinicalTrials portal.